Alpha 2.0
Login Register
» Articles » PMID: 9559787

Zidovudine Pharmacokinetics in Premature Infants Exposed to Human Immunodeficiency Virus

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1998 Apr 29
PMID 9559787
Citations 15
Authors
M Mirochnick
E Capparelli
W Dankner
R S Sperling
R Van Dyke
S A Spector
Affiliations
Soon will be listed here.
Abstract

We used population analysis techniques to determine zidovudine (ZDV) pharmacokinetic parameters in 15 preterm neonates (mean gestational age, 29.4 weeks; mean birth weight, 1,230 g) at a mean age of 5.5 days. The values of the pharmacokinetic parameters were as follows: clearance, 2.53 +/- 0.44 ml/min/kg; volume of distribution, 1.59 +/- 0.51 liters/kg; and half-life, 7.2 +/- 1.5 h. For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found. The ZDV clearance is low and the half-life is prolonged in premature neonates, but the clearance increases and the half-life decreases with postnatal age. Potentially toxic concentrations may accumulate in serum if the standard dosage for full-term infants is used. We suggest that initial ZDV dosing should be reduced to 1.5 mg every 12 h for preterm neonates.

Citing Articles

Pediatric AIDS-Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling.

Capparelli E J Pediatr Pharmacol Ther. 2022; 27(6):482-489.

PMID: 36042957 PMC: 9400182. DOI: 10.5863/1551-6776-27.6.482.

Getting to 90-90-90 in paediatric HIV: What is needed?.

Davies M, Pinto J, Bras M J Int AIDS Soc. 2017; 18(7Suppl 6):20770.

PMID: 28326130 PMC: 4813611. DOI: 10.7448/IAS.18.7.20770.

The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.

Cotton M, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M J Int AIDS Soc. 2015; 18(Suppl 6):20271.

PMID: 26639118 PMC: 4670832. DOI: 10.7448/IAS.18.7.20271.

Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.

Mahmood I Eur J Drug Metab Pharmacokinet. 2014; 40(1):53-9.

PMID: 24519316 DOI: 10.1007/s13318-014-0178-9.

Pharmacotherapy of pediatric HIV infection.

Rakhmanina N, Phelps B Pediatr Clin North Am. 2012; 59(5):1093-115.

PMID: 23036246 PMC: 3465562. DOI: 10.1016/j.pcl.2012.07.009.

References
1.
Connor E, Sperling R, Gelber R, Kiselev P, Scott G, OSullivan M . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. DOI: 10.1056/NEJM199411033311801. View
2.
Abrams E, Matheson P, Thomas P, Thea D, Krasinski K, Lambert G . Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. New York City Perinatal HIV Transmission Collaborative Study Group. Pediatrics. 1995; 96(3 Pt 1):451-8. View
3.
Volberding P, Lagakos S, Koch M, Pettinelli C, Myers M, Booth D . Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990; 322(14):941-9. DOI: 10.1056/NEJM199004053221401. View
4.
McKinney Jr R, Maha M, Connor E, Feinberg J, SCOTT G, Wulfsohn M . A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991; 324(15):1018-25. DOI: 10.1056/NEJM199104113241503. View
5.
. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep. 1994; 43(RR-11):1-20. View